Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesVaxcyte Inc

Vaxcyte Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
68.62 USD 2.26 ( 3.41%)
Last update at 2026-11-11T21:27:00Z
VOLUME
1617166
Market Cap
8810.76M

Momentum Score

…

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
66.56
Low
68.92
High
52 Week Price Range
30.89
Low
65.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Vaxcyte is a clinical-stage biotechnology company developing vaccines using a proprietary platform, with a lead 24-valent pneumococcal conjugate vaccine candidate and a pipeline of additional vaccine programs. Long-term growth could be driven by late-stage progress and potential approval of its pneumococcal candidate, platform-enabled pipeline expansion, and in-house manufacturing capabilities that may support commercial scale and broader market access.
Key investment risks include clinical and regulatory failure for lead candidates, strong competition from incumbent vaccine manufacturers, and ongoing financing and commercialization execution challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
66.36
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-75.00M
Debt / Equity
0.09
ROE
-36.51%
Net Debt
54.88M
ROCE
-26.99%
Diluted EPS TTM
-7.59

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -766.63M -463.93M -402.27M -223.49M -100.08M
Net income -766.63M -463.93M -402.27M -239.64M -100.08M
Selling general administrative 129.37M 92.90M 60.70M 39.81M 25.26M
Selling and marketing expenses - - 10.17M - -
Gross profit - -15.85M -75.00M - -
Reconciled depreciation 24.86M 15.85M 10.17M 9.20M 3.46M
Ebit -766.63M -463.93M -402.27M -232.26M -103.67M
Ebitda -741.77M -448.08M -392.10M -189.78M -98.28M
Depreciation and amortization 24.86M 15.85M 10.17M 42.48M 5.39M
Non operating income net other - - - - 3.59M
Operating income -923.67M -569.55M -468.04M -232.26M -103.67M
Other operating expenses 923.67M 569.55M 468.04M 207.33M 102.08M
Interest expense - 0.00M 0.00M 0.00M 0.01M
Interest income 119.72M 109.99M 62.91M 8.36M 0.34M
Net interest income 119.72M 109.99M 62.91M 8.35M 0.34M
Income tax expense - - -402.27M 16.16M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 923.67M 569.55M 468.04M 207.33M 102.08M
Cost of revenue - 15.85M 75.00M - -
Total other income expense net 157.05M 105.62M 65.78M 8.77M 3.59M
Net income from continuing ops -766.63M -463.93M -402.27M -223.49M -100.08M
Net income applicable to common shares - - - -223.49M -100.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3045.97M 3511.32M 1407.92M 1006.18M 324.34M
Other current assets 19.84M 20.11M 12.12M 11.18M 10.38M
Total liab 360.45M 205.50M 167.45M 52.56M 40.32M
Total stockholder equity 2685.51M 3305.82M 1240.47M 953.61M 284.02M
Deferred long term liab - - - 0.50M 0.50M
Other current liab 128.72M 85.84M 123.64M 24.82M 16.68M
Common stock 0.13M 0.13M 0.10M 0.08M 0.06M
Capital stock 0.13M 0.13M 0.10M 0.08M 0.06M
Retained earnings -2154.95M -1388.32M -924.39M -522.13M -298.64M
Other liab - - - 0.01M 0.10M
Other assets - - 0.00M 5.43M 4.96M
Cash 173.96M 387.88M 397.45M 834.66M 68.98M
Total current liabilities 205.75M 140.18M 145.34M 40.52M 28.72M
Net debt 54.88M -316.77M -368.23M -816.72M -52.20M
Short term debt 6.12M 5.89M 7.11M 5.91M 5.28M
Short long term debt total 228.84M 71.11M 29.22M 17.94M 16.78M
Other stockholder equity 4838.74M 4697.88M 2164.58M 1476.02M 258.51M
Property plant equipment - - - 31.65M 35.91M
Total current assets 1627.36M 1787.98M 1095.95M 942.55M 256.35M
Long term investments 881.66M 1387.51M 162.68M 26.55M 27.12M
Net tangible assets - - - 953.61M 284.02M
Short term investments 1387.00M 1359.33M 682.78M 96.72M 176.99M
Net receivables 46.56M 20.66M 3.61M 1.00M 1.20M
Accounts payable 70.90M 48.45M 14.59M 9.79M 6.76M
Accumulated other comprehensive income 1.59M -3.87M 0.18M -0.36M -0.24M
Common stock total equity - - - - 0.06M
Retained earnings total equity - - - - -298.64M
Non currrent assets other 0.51M 65.68M 37.56M 5.43M 4.96M
Non current assets total 1418.60M 1723.33M 311.96M 63.62M 67.99M
Capital lease obligations 117.48M 71.11M 29.22M 17.94M 16.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 494.33M -2005.67M -773.31M 74.58M -212.31M
Change to liabilities - - - 2.90M -12.47M
Total cashflows from investing activities 437.35M -2005.67M -773.31M 74.58M -212.31M
Total cash from financing activities 2.01M 2448.51M 639.81M 861.55M 17.80M
Change to operating activities - - - 9.84M -24.54M
Net income -766.63M -463.93M -402.27M -223.49M -100.08M
Change in cash -213.77M -9.36M -436.97M 765.67M -316.34M
Begin period cash flow 389.19M 398.55M 835.53M 69.86M 386.20M
End period cash flow 175.43M 389.19M 398.55M 835.53M 69.86M
Total cash from operating activities -655.58M -452.63M -296.79M -170.60M -121.39M
Issuance of capital stock 0.00M 2435.66M 636.04M 856.48M 13.90M
Depreciation 24.86M 15.85M 10.17M 9.20M 3.46M
Other cashflows from investing activities -43.26M -96.73M - - 0.03M
Sale purchase of stock - - 2.04M 1.03M 0.89M
Other cashflows from financing activities -10.99M 12.85M 3.77M 4.03M 3.01M
Change to netincome - - - 30.95M 12.23M
Capital expenditures 13.71M 22.43M 67.88M 5.85M 6.55M
Cash flows other operating - - - - -30.68M
Cash and cash equivalents changes - - - - -315.90M
Change in working capital -3.45M -54.90M 81.32M 12.74M -37.01M
Stock based compensation 138.84M 84.82M 48.76M 23.65M 10.73M
Other non cash items -49.20M -34.47M -34.77M 7.30M 1.50M
Free cash flow -669.29M -475.05M -364.67M -176.44M -127.95M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
PCVX
Vaxcyte Inc		 2.26
3.41%		 68.62 - - - 3.21 -14.43
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

825 Industrial Road, San Carlos, CA, United States, 94070

650 837 0111

https://vaxcyte.com

507

Name Title Year Born
Mr. Grant E. Pickering M.B.A. Co-Founder, CEO & Director 1968
Mr. Andrew L. Guggenhime M.B.A. Pres, CFO & Principal Accounting Officer 1968
Mr. James Wassil M.B.A., M.S. Exec. VP & COO 1969
Mr. Paul W. Sauer M.B.A., MBA Sr. VP of Process Devel. & Manufacturing 1961
Mr. Harp Dhaliwal M.B.A. Sr. VP of Commercial Manufacturing & Supply Chain 1973
Dr. Ashish Khanna M.B.A., Ph.D. Co-Founder and Chief Bus. Officer 1972
Dr. Jeff Fairman Ph.D. Co-Founder & VP of Research 1964
Ms. Janet Graesser VP of Corp. Communications & Investor Relations NA
Mr. Mikhail Eydelman J.D. Sr. VP, Gen. Counsel & Corp. Sec. 1978
Karen Alderete Exec. Director of HR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…